- Advertisement -
The government is closely monitoring the clinical trial of molnupiravir, an investigational drug that is slated to be the first oral antiviral medication for COVID-19.
“That would be a big help once findings show that it is effective for the patients,” Vergeire said.
Molnupiravir, an oral pill developed by Merck and Ridgeback Biotherapeutics, is designed to prevent the replication of several RNA viruses, including the SARS-CoV-2 virus that causes COVID-19.
Merck said the drug had significantly reduced by about 50 percent the risk of hospitalization or death among COVID-19-positive individuals who joined its late-stage trial.
- Advertisement -